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Mutations of SCN5A gene, which encodes the α-subunit of the voltage-gated Na channel
NaV1.5, underlie hereditary cardiac arrhythmic syndromes such as the type 3 long QT syn-
drome, cardiac conduction diseases, the Brugada syndrome, the sick sinus syndrome, a trial
standstill, and numerous overlap syndromes. Patch-clamp studies in heterologous expres-
sion systems have provided important information to understand the genotype-phenotype
relationships of these diseases. However, they could not clarify how SCN5A mutations can
be responsible for such a large spectrum of diseases, for the late age of onset or the pro-
gressiveness of some of these diseases and for the overlapping syndromes. Genetically
modified mice rapidly appeared as promising tools for understanding the pathophysiological
mechanisms of cardiac SCN5A-related arrhythmic syndromes and several mouse models
have been established. This review presents the results obtained on these models that,
for most of them, recapitulate the clinical phenotypes of the patients. This includes two
models knocked out for Nav1.5 β1 and β3 auxiliary subunits that are also discussed. Despite
their own limitations that we point out, the mouse models still appear as powerful tools
to elucidate the pathophysiological mechanisms of SCN5A-related diseases and offer the
opportunity to investigate the secondary cellular consequences of SCN5A mutations such
as the expression remodeling of other genes. This points out the potential role of these
genes in the overall human phenotype. Finally, they constitute useful tools for addressing
the role of genetic and environmental modifiers on cardiac electrical activity.
+
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Mutations in the SCN5A gene, which encodes the α-subunit of the
cardiac voltage-gated Na+ channel NaV1.5, underlie hereditary
arrhythmic syndromes (so-called cardiac channelopathies). On
one hand, gain-of-function mutations, that increase the late com-
ponent of the Na+ current (I Na) and thus prolong the ventricular
action potential, are responsible for the type 3 long QT syndrome
(LQT3; Moss and Kass, 2005). On the other hand, loss-of-function
mutations decrease I Na and are responsible for cardiac conduction
diseases (Schott et al., 1999; Tan et al., 2001; Probst et al., 2003),
Brugada syndrome (Gussak et al., 1999), sick sinus syndrome
(Benson et al., 2003), and atrial standstill (Groenewegen et al.,
2003). To complicate matters further, some SCN5A mutations can
lead to more complex diseases associating different phenotypic
traits such as, for instance, bradycardia, conduction disease, LQT3,
and Brugada syndrome (so-called overlap syndromes; Bezzina
et al., 1999; Kyndt et al., 2001; Grant et al., 2002; Rossenbacker
et al., 2004; Smits et al., 2005; for review, see Remme et al., 2008).
Finally, there is also an association between SCN5A genetic defects
and susceptibility to dilated cardiomyopathy (DCM; McNair et al.,
2004) and atrial fibrillation (Laitinen-Forsblom et al., 2006; Ellinor
et al., 2008).
Although patch-clamp studies in heterologous expression sys-
tems have provided a great deal of information to understand the
genotype-phenotype relationships of these diseases, these models
could not clarify how loss-of-function-mutations can be respon-
sible for such a large spectrum of diseases and the late age of onset
or the progressiveness of some of them. They are even less adapted
to overlap syndromes.
Genetically modified mice thus appeared as promising tools
for understanding the pathophysiological sequence of cardiac
SCN5A-related channelopathies and several mouse models have
been established (Table 1). Fortunately, whereas some geneti-
cally modified mice related to K+ channel dysfunction did not
reach investigators’ expectations because of major electrophys-
iological differences between mice and men (Nerbonne et al.,
2001; Charpentier et al., 2004), mouse models of inherited SCN5A
channelopathies, on the contrary, appeared to be informative.
MODELS FOR THE LQT3 SYNDROME
SCN5A-related long QT syndrome (LQT3; Wang et al., 1995) is less
frequent but often more lethal than LQT1 and LQT2 (Priori et al.,
2003). Like in other LQT syndromes, the abnormal prolongation
of ventricular repolarization is associated with a susceptibility to
a specific polymorphic ventricular tachycardia called torsades de
pointes and ventricular fibrillation, leading to syncope and sudden
death. Clinically, LQT3 is characterized by an increased duration of
the ST segment with a late appearance of the T-wave (Moss, 2002).
Bradycardia and pauses occurring at rest, and more particularly
during sleep, are often at the origin of the arrhythmias. However,
fatal tachycardia-induced arrhythmias have also been reported for
a third of the patients (Schwartz et al., 2001). Two thirds of the
SCN5A mutations found in LQT3 alter the fast inactivation process
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Table 1 | Mouse models of SCN5A-related cardiac genetic diseases.
Mouse Genetic
modification
Human disease ECG phenotype Arrhythmias Effect on INa Original
publication
Scn5a∆/+ KI/heterozygote/
150-5KPQ-1507
del
LQT3 QT prolongation VT EADs in vitro Increased late current Nuyens et al.
(2001), Head
et al. (2005)
hSCN5A-
N1325S
Tg/point mutation LQT3 QT prolongation VT EADs in vitro Delayed inactivation
increased late current
Tian et al.
(2004)
Scn5a± KO/heterozygote Brugada, PCCD P wave, PR and QRS
prolongation
Triggered VT
(spontaneous in old)
≈50% decrease in peak
current
Papadatos
et al. (2002)
Scn5a1798insD/+ KI/heterozygote/
insertion
Overlap syndrome
(LQT3 – Brugada –
CCD)
PR, QRS and QT
prolongation
Sinus pauses EADs
in vitro
≈40% decrease in peak
current, increased late
current
Remme et al.
(2006)
SCN5A-
D1275N
RMCE/hetero-
and homozygote/
point mutation
Arrhythmogenic
DCM
Bradycardia, P wave,
PR and QRS
prolongation
AT/AF, VT and sinus
node dysfunction in
homozygote
≈50% decrease in peak
current (heterozygote)
Watanabe
et al. (2011)
Scn1b−/− KO/hetero- and
homozygote
LQT3 Bradycardia and QT
prolongation
(homozygote)
Not investigated ≈60% increase in peak
and late current
(homzygote)
Lopez-
Santiago et al.
(2007)
Scn3b−/− KO/homozygote Brugada, CCD Bradycardia, P wave
and PR prolongation
Triggered VT
spontaneous and
triggered AT
≈50% decrease in peak
current, negative shift of
steady-state inactivation
Hakim et al.
(2008)
AT, atrial tachycardia; AF, atrial fibrillation; DCM, dilated cardiomyopathy; del, deletion; EAD, early afterdepolarization; KI, knock-in; KO, knockout; LQT3, type 3 long QT
syndrome; PCCD, progressive cardiac conduction defects; RMCE, recombinase mediated cassette exchange; VT, ventricular tachycardia; Tg, transgenic.
of the channel (Zimmer and Surber, 2008). For example, the first
identified mutation, which leads to the deletion of three amino
acids (1505-KPQ-1507) in the inactivation domain of NaV1.5,
results in a persistent inward Na+ current (Wang et al., 1996)
and prolongation of the action potential plateau phase (Moss and
Kass, 2005).
SCN5A∆1505-1507KPQ/+ KNOCK-IN MOUSE
Nuyens et al. (2001) generated a knock-in mouse model lack-
ing the same KPQ residues. Mice heterozygous for this muta-
tion (Scn5a∆/+) showed typical features of the LQT3 syndrome
and spontaneously developed ventricular arrhythmias. Compared
with wild-type mice, transmembrane action potentials recorded
in ventricular preparations were markedly prolonged in Scn5a∆/+
mice and showed a steeper “heart rate” versus “action poten-
tial duration” relationship (Nuyens et al., 2001). Action potential
amplitude and upstroke velocity were not altered. Whole-cell
patch-clamp recordings performed on cardiomyocytes confirmed
the increase in late inward Na+ current previously observed in
heterologous expression system, which explains the action poten-
tial prolongation (Wang et al., 1996). Surprisingly, there was also
a two-fold increase in the peak Na+ current density, which could
not be explained by an over-expression of NaV1.5 or changes in
the steady-state activation and inactivation of the current. How-
ever, this finding was not confirmed in a more recent study on the
same model (Fredj et al., 2006) and the reason for this discrepancy
remains to be clarified. Nuyens et al.’s (2001) study also revealed
an acceleration of the recovery from inactivation, a property that
might favor re-entrant arrhythmias. Indeed, intracardiac pacing
with extra stimuli, short-long-short pacing sequences and abrupt
accelerations of heart rate reproducibly induced polymorphic ven-
tricular arrhythmias in Scn5a∆/+ mice but not in wild-type mice.
The Scn5a∆/+ mice were also characterized by a paradoxical tran-
sient action potential prolongation upon abrupt acceleration of
pacing rate that favored the occurrence of early after depolariza-
tions. This prolongation was blocked by the Na+ channel blocker
mexiletine and the adrenergic agonist isoproterenol. It can be
explained by the increase of both fast and slow components of
the Na+ current which causes a sudden increase of Na+ load,
and secondarily of Ca2+ load. As a consequence, during each
action potential, the increased Ca2+ release from the sarcoplas-
mic reticulum activates a larger Na/Ca exchanger current which
generates early after depolarizations. The autonomic modulation
of cardiac electrical activity and arrhythmias of Scn5a∆/+ mice
has been recently investigated in more details both in vivo in freely
moving mice and ex vivo (Fabritz et al., 2010). As expected from
clinical investigations, cholinergic stimulation was shown to favor
arrhythmias by inducing bradycardia. In contrast, β-adrenergic
stimulation suppressed arrhythmias by shortening repolarization
and increasing cardiac rate, while β-blockers had no effect on
their own.
A second Scn5a∆/+ mouse line, exhibiting the same phenotype
as the previous line, was created (Head et al., 2005) and submit-
ted to an extended pharmacological analysis. Electrophysiological
studies performed on Langendorff-perfused whole hearts con-
firmed the anti-arrhythmic properties of mexiletine (Fabritz et al.,
2003; Head et al., 2005) and showed that another Na+ channel
inhibitor, flecainide, could also prevent arrhythmias by preferen-
tially inhibiting the late Na+ current (Fredj et al., 2006), whereas
β-blockers were inefficient (Head et al., 2005; Stokoe et al., 2007b;
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Sabir et al., 2008). These results have been confirmed in freely mov-
ing mice (Fabritz et al., 2010). More recently, it was shown that a
specific inhibition of the L-type Ca2+ channels with nifedipine
was also efficient in preventing arrhythmias through the suppres-
sion of early after depolarizations (Thomas et al., 2007). Finally,
nicorandil, an activator of the ATP-sensitive K+ channel, also
reduces arrhythmogenicity in Scn5a∆/+ mice (Hothi et al., 2008),
confirming previous results obtained with the canine wedge prepa-
ration pharmacological model of LQT3 (Shimizu and Antzele-
vitch, 2000). In contrast, quinidine was proarrhythmic (Sabir
et al., 2008). Ex vivo studies also confirmed the key role played
by bradycardia and increased dispersion of repolarization on the
occurrence of spontaneous ventricular arrhythmias (Fabritz et al.,
2003). Sudden rate accelerations initially and transiently increased
the dispersion of repolarization due to early after depolarizations
and action potential alternans (Fabritz et al., 2003; Hothi et al.,
2008),as previously observed in vivo (Nuyens et al.,2001),and then
secondarily suppressed and prevented ventricular tachycardia by
decreasing dispersion of repolarization and suppressing early after
depolarizations. Arrhythmogenesis, as assessed by programmed
electrical stimulation on Langendorff-perfused hearts, has also
been associated with abnormal patterns of myocardial activation
and abnormally reduced transmural gradients of repolarization
resulting from a larger increase in action potential duration in
subepicardium than in subendocardium (Stokoe et al., 2007b). In
addition, Scn5a∆/+ mice exhibit larger differences between action
potential duration and refractory period, so-called local critical
interval (APD-ERP), in subepicardial regions than in wild-type
mice. Those anomalies may support re-entrant events following
premature excitation. More recently, Sabir et al. (2008) proposed
that the increases of the slopes of restitution curves (plotting action
potential duration versus the preceding diastolic interval; Gilmour,
2003) to values greater than one, rather than increased dispersion
of repolarization, was associated with arrhythmogenicity. All these
anomalies, including action potential alternans are corrected by
nicorandil (Hothi et al., 2008).
Altogether, Scn5a∆/+ mice recapitulate most of the LQT3 asso-
ciated clinical symptoms. They confirmed previous studies sug-
gesting that arrhythmias in LQT3 syndrome may result from
reentries provoked by early after depolarizations and enabled to
unveil the mechanisms of tachycardia-induced arrhythmias. Stud-
ies of Scn5a∆/+ mice have also provided a rationale for the use of
Na+ channel blockers and pacing to prevent cardiac arrhythmias
and sudden death in the context of LQT3, for which β-blockers
have shown low efficacy. Finally, they suggest that Ca2+ channels
inhibitors and ATP-sensitive K+ channel activators might be inter-
esting pharmacological approaches to prevent arrhythmias in this
context.
In addition to early after depolarizations, the occurrence of
delayed after depolarizations, resulting from the transient inward
current (I ti), was also clearly demonstrated in myocytes of
Scn5a∆/+ mice (Fredj et al., 2006). Most recently, Lindegger et al.
(2009) showed that I ti induction occurs under conditions of ele-
vated sarcoplasmic reticulum Ca2+ content that is most probably
related to the mutation-induced increase in late Na+ current.
Indeed, both I ti and its underlying Ca2+ wave were suppressed
by ranolazine, an antianginal agent well known to block the late
Na+ current (Hale et al., 2008). Whether delayed after depolariza-
tions participate to spontaneous arrhythmic events in Scn5a∆/+
mice, and of course in LQT3 patients, remains to be determined.
Investigating the potential anti-arrhythmic effects of ranolazine in
this model also remains to be performed.
Patients with LQT syndrome (El Yaman et al., 2008; Johnson
et al., 2008; Zellerhoff et al., 2009), including LQT3 (Benito et al.,
2008), may be at increased risk for atrial fibrillation. Therefore,
the atrial phenotype of Scn5a∆/+ mice was characterized. Using
Langendorff-perfused hearts, Blana et al. (2010) showed that atrial
action potential duration and effective refractory period were pro-
longed in Scn5a∆/+ mice. Short runs of rapid pacing-induced
a larger increase in post-pacing spontaneous atrial cycle length
and action potential duration in Scn5a∆/+ mice than in wild-type
mice, leading to the occurrence of atrial tachycardia in Scn5a∆/+
mice but not in wild-type mice. Extra stimuli triggered arrhyth-
mias similarly in wild-type and Scn5a∆/+ mice (in 30–40% of
the mice). Contrasting results had been previously observed with
the second mouse line suggesting that Scn5a∆/+ mice are pro-
tected against pacing-induced atrial tachyarrhythmias when young
(3 months; Dautova et al., 2009), whereas they exhibit an increased
atrial arrhythmogenicity when old (1 year; Guzadhur et al., 2010).
Without excluding the influence of variable experimental condi-
tions, those discrepancies might also rely on the fact that the two
lines have different genetic backgrounds, as we will discuss later
for the Scn5a1798insD/+ knock-in mouse. Both mouse lines, how-
ever, exhibit decreased heart rate and atrioventricular conduction
(prolonged PR interval) versus wild-type mice.
Sinus node dysfunction has been reported in patients with
SCN5A-related long QT syndrome whether these mutations only
lead to an increased late Na+ current (Moss et al., 1995; Wei et al.,
1999) or lead to more complex biophysical alterations of the chan-
nel (Bezzina et al., 1999; van den Berg et al., 2001; Grant et al.,
2002). Because QT prolongation is more pronounced at lower
heart rates, bradycardia represents an important indirect factor in
predisposition to lethal arrhythmias in LQT3 families (Schwartz
et al., 1995). The mechanisms for LQT3-related bradycardia were
investigated for the 1795insD mutation of NaV1.5 (Veldkamp et al.,
2003), a mutation inducing an overlap syndrome with bradycar-
dia, conduction disease, LQT3 and Brugada syndrome (Bezzina
et al., 1999). This mutation induces both a decrease in Na+ peak
current and the occurrence of a late Na+ current (see dedicated
section below for details). By combining current clamp studies and
computational modeling, Veldkamp et al. (2003) suggested that
both the decreased availability of Na+ channels and the increase
of late current accounted for bradycardia. However, the effect of
action potential prolongation secondary to the increased late cur-
rent appeared more prominent. The contribution of the late Na+
current to sinus node dysfunction has been further confirmed on
Scn5a∆/+ mice (Wu et al., 2012). Scn5a∆/+ mice exhibit sinus
node dysfunction with episodes of bradycardia, sinus pauses, and
longer sinus node recovery times. Sino-atrial preparations from
Scn5a∆/+ mice had lower intrinsic rate from the sinus node to
the surrounding atrium than wild-type preparations. Computa-
tional studies confirmed that the decrease in sinus rate could be
attributed to the increased late current. Ex vivo experiments on
sino-atrial preparations also showed that conduction through the
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sinus node to the surrounding atrium was decreased, a result that
computer modeling could only explain by a decrease in Na+ peak
current amplitude, which has not been experimentally confirmed.
hSCN5A-N1325S TRANSGENIC MOUSE MODEL
The N1325S mutation of NaV1.5, located in the intracellular
region between segments 4 and 5 of domain III, also causes
LQT3 syndrome (Wang et al., 1995). This mutation, like many
similar mutations, leads to an increased late inward Na+ current
(Dumaine et al., 1996; Wang et al., 1996). A transgenic mouse with
cardiac selective expression of human SCN5A-N1325S mutation
under the control of the mouse α-myosin heavy chain promoter
was established (Tian et al., 2004). Transgenic mice showed some
of the typical features of the LQT3 syndrome such as prolonged
QT interval, ventricular arrhythmias, and a high rate of sudden
deaths due to documented polymorphic ventricular tachycardia
and ventricular fibrillation. However, transgenic mice were also
characterized by increased heart rate and shorter PR intervals that
are not observed in LQT3 patients. Some of these features might
result from over-expression of the channel rather than from the
mutation itself since short PR interval was also observed in the
control mouse over-expressing wild-type hSCN5A gene (Zhang
et al., 2007).
Voltage-clamp experiments on cardiomyocytes isolated from
wild-type and hSCN5A-N1325S mice confirmed that the N1325S
mutation does not modify the peak current but delays the inac-
tivation process and generates a late persistent current (Tian
et al., 2004), which decreases with increasing pacing rates (Yong
et al., 2007). Action potentials from hSCN5A-N1325S ventricu-
lar myocytes were longer than wild-type ones and exhibited early
after depolarizations. As in Scn5a∆/+ mice, mexiletine shortened
ventricular action potential duration and prevented arrhythmias
(Tian et al., 2004). Interestingly, action potential duration of trans-
genic but not wild-type myocytes paradoxically increased with
pacing rate (Tian et al., 2004) and became highly variable with
occurrence of repolarization alternans (Yong et al., 2007). Whether
this phenomenon was only transient, as in Scn5a∆/+ mice, or per-
sisted during long periods of increased pacing rate is unclear. The
Ca2+ channel blocker verapamil reduced these alternans, suggest-
ing an involvement of intracellular Ca2+ deregulation in this phe-
nomenon. Previous studies had shown that patients with long QT
syndrome can exhibit T-wave alternans during sinus tachycardia
(Cruz Filho et al., 2000; Viskin et al., 2004).
Like the Scn5a∆/+ mouse model, the hSCN5A-N1325S mouse
provided key information to our understanding of arrhythmias in
LQT3 syndrome. For instance, it showed that the N1325S mutant
dysfunction can explain both bradycardia- and non-bradycardia-
related arrhythmias observed in patients carrying this mutation
(Yong et al., 2007). However, the model might be taken with cau-
tion because of the limitations linked to the over-expression of the
channel. Indeed, there is a clear relationship between the level of
hSCN5A-N1325S expression and the extent of QT prolongation,
i.e., by 23% with 1–2 copies and by 91% with 10 copies. Most
recently, this model was shown to exhibit cardiomyocyte apop-
tosis, cardiac fibrosis, and contractile dysfunction during aging
(Zhang et al., 2011). But signs of heart failure were markedly
larger in the mouse line with 10 copies. Although heart failure
is probably not related to SCN5A over-expression per se, because
old mice over-expressing 10 times the wild-type channel remained
normal, one should better consider the model over-expressing the
least the mutant channel to extrapolate the results to the patients.
In this second line, left ventricular fractional shortening was less
decreased and only 30% of the mice showed features of DCM, a
result more consistent with the scarcity of heart failure in LQT3
patients (Nguyen et al., 2008; Shi et al., 2008).
A MODEL FOR THE BRUGADA SYNDROME AND
CONDUCTION DISORDERS: THE Scn5a KNOCKOUT MOUSE
The Brugada syndrome is a genetic disease which associates ST
segment elevation in the right precordial leads V1 to V3 of the
ECG, often with signs of conduction slowing, with a high risk of
sudden cardiac death secondary to ventricular tachycardia or fib-
rillation (Gussak et al., 1999; Antzelevitch et al., 2005). In 20–30%
of the patients, the disease is related to mutations in SCN5A lead-
ing to a complete or partial loss-of-function of NaV1.5 (Tan et al.,
2003). Loss-of-function mutations are also responsible for inher-
ited Progressive Cardiac Conduction Defects (PCCD), also called
Lev-Lenègre disease (Schott et al., 1999), or non-progressive con-
duction defects (Tan et al., 2001). More recently, PCCD has also
been linked to gain-of-function mutations in TRPM4 gene (Tran-
sient Receptor Potential cation channel, subfamily M, member
4), which encodes a Ca2+-activated non-selective channel (Kruse
et al., 2009; Liu et al., 2010). PCCD is a slowly evolving disease
which progressively affects cardiac conduction leading ultimately
to pacemaker implantation to prevent the risk of complete atri-
oventricular block and Stokes–Adams syncope. Inherited PCCD
associates haploinsufficiency of SCN5A together with an addi-
tional yet unknown mechanism related to aging (Probst et al.,
2003). Despite their major clinical differences, Brugada syndrome,
and inherited conduction diseases share common features. First,
both diseases can be caused by SCN5A haploinsufficiency. Second,
Brugada patients with SCN5A mutations exhibit altered conduc-
tion whereas Brugada patients without SCN5A mutations do not
(Smits et al., 2002). Finally, both Brugada syndrome and PCCD
can be found in the same pedigree (Kyndt et al., 2001). In other
families, patients carrying loss-of-function mutations can exhibit
symptoms of Brugada syndrome, conduction disease, and sick
sinus syndrome, either combined or not (Smits et al., 2005). Severe
forms of sick sinus syndrome have also been found in patients with
double inheritance of SCN5A loss-of-function mutations (Benson
et al., 2003).
A mouse model with targeted disruption of Scn5a gene has
been established (Papadatos et al., 2002). Homozygous knockout
mouse embryos die during mid-gestation due to severe defects in
ventricular morphogenesis whereas heterozygous (Scn5a±) mice
show normal survival. However, 8- to 10-week-old Scn5a± mice
have several cardiac electrical defects such as decreased atrial
and atrioventricular conduction and increased susceptibility to
pacing-induced ventricular arrhythmias (Papadatos et al., 2002).
Following this initial report, the model was further analyzed to
investigate the potential pathophysiological mechanisms involved
in the progressive evolution of SCN5A-related PCCD (Royer et al.,
2005; van Veen et al., 2005). It was found that in addition to atrial
and atrioventricular conduction, ventricular conduction was also
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decreased. Moreover, ECG studies performed on mice ranging
from 4 to 71 weeks of age showed that the ventricular phenotype
of Scn5a± mice worsened with age. This feature was confirmed by
activation mapping studies performed on Langendorff-perfused
hearts. In young Scn5a± mice, conduction velocity was only
affected in the right ventricle. In old mice, right ventricular con-
duction defect worsened and was in addition associated with
conduction velocity defect in the left ventricle. This age-dependent
deterioration of ventricular conduction was associated with the
occurrence of fibrosis in ventricular myocardium. In some aspects,
this phenotype resembles PCCD, although in the later fibrosis was
found to be limited to the conduction system area (Lenègre and
Moreau, 1963; Lev, 1964). However, it is worth noting that fibro-
sis has also been observed in patients with the Brugada syndrome
(Coronel et al., 2005; Frustaci et al., 2005). More recently, it was
shown that Scn5a± mice display variable degrees of conduction
defects when young (10 weeks old): some mice have only mild pro-
longation of the QRS interval while others have more severe QRS
prolongation associated with RR′ or SS′ patterns (Leoni et al.,
2010). The extent of fibrotic remodeling was dependent on the
severity of the initial conduction disorders: mice with larger QRS
prolongation when young have the most severe fibrotic remodel-
ing when they get older, suggesting that the ventricular activation
pattern is a key element for triggering remodeling. Whatever their
triggering mechanism, fibrosis, and redistribution of connexin 43
expression most likely contribute to the age-dependent degra-
dation of ventricular conduction in the mouse model. Whether
SCN5A-related inherited PCCD in human also results from a pri-
mary decrease in Na+ current and a secondary progressive fibrosis
with aging remains to be clarified. In this context, Scn5a± mice
could be used for testing preventive therapies as an alternative to
pacemaker implantation.
In their initial report on the Scn5a± mouse model, Papadatos
et al. (2002) showed that programmed ventricular electrical pacing
of Langendorff-perfused hearts induced ventricular tachyarrhyth-
mias in two thirds of Scn5a± mice but not in wild-type mice
and proposed that the model could be used for elucidating the
mechanisms of arrhythmias in the context of SCN5A-related Bru-
gada syndrome. Pathophysiological findings have implicated the
right ventricular outflow tract as the primary location for elec-
trical disorders in Brugada syndrome. Two hypotheses have been
proposed to explain both ST segment elevation and occurrence of
arrhythmias (Wilde et al., 2010). The first one, mainly based on
experimental data obtained in arterially perfused canine right ven-
tricular wedges, implicates alterations in transmural and regional
repolarization gradients leading to localized losses of the subepi-
cardial action potential dome and phase 2 reentries as the arrhyth-
mogenic mechanism. The second one, mainly based on clinical
studies, implicates abnormal conduction. To elucidate the arrhyth-
mogenic mechanisms in Scn5a± mice programmed electrical
stimulation, monophasic action potential (MAP) recording, and
bipolar electrogram recording was performed on Langendorff-
perfused hearts. These experiments showed that Scn5a±mice were
characterized by increased electrogram duration with shortening
extrasystoles intervals, especially in the right ventricular outflow
tract, and increased transmural and regional heterogeneity of
MAP duration and refractory periods in the right ventricle with
the shortest in the right ventricular outflow tract (Stokoe et al.,
2007a; Martin et al., 2010, 2011a,b). Scn5a± mice also exhibited
increased incidence of MAP alternans. As a consequence, ventric-
ular tachycardia occurred earlier in the right ventricular outflow
tract (Martin et al., 2011b). All these mechanisms were potentiated
by flecainide, a Na+ channel inhibitor which is well described to
favor ST segment elevation and arrhythmias in patients with the
Brugada syndrome. Ventricular tachycardia also occurred sponta-
neously both in vivo (Leoni et al., 2010; Martin et al., 2011c) and ex
vivo (Martin et al., 2011d), but with a much higher incidence under
flecainide treatment (Martin et al., 2011c,d). Multielectrode array
studies showed that the initiation of spontaneous arrhythmias
resulted from a combination of conduction slowing and repo-
larization heterogeneities leading to lines of conduction blocks
and unidirectional conduction (Martin et al., 2011d). Altogether
these results seem to contradict the hypothesis that arrhythmias
in the Brugada syndrome result from phase 2 re-entrant mecha-
nisms. However, the main limitation of the mouse model is that
the ventricular action potential lacks a plateau phase, and for the
subepicardial action potential, a spike, and dome morphology,
present in larger mammals and prerequisite for phase 2 reentries.
In addition, Scn5a± mice turned out to be useful for under-
standing the role of NaV1.5 in sinus node normal function and
the pathophysiology of sinus node dysfunction associated to
SCN5A loss-of-function mutations (Benson et al., 2003; Smits
et al., 2005). Indeed, Scn5a± mice also display moderate brady-
cardia that can be associated with occasional sino-atrial blocks
in older animals (Lei et al., 2005). Lei et al. showed that small
central sino-atrial node cells, which do not express NaV1.5, exhib-
ited normal intrinsic pacemaker rate. In contrast, larger peripheral
sino-atrial node cells, which normally express NaV1.5, exhibited
reduced intrinsic pacemaker rate associated to reduced expression
of NaV1.5. These data were consistent with the slower sino-atrial
conduction and frequent sino-atrial conduction blocks observed
in Scn5a± sino-atrial node preparations compared to wild-type
although they exhibited normal activation patterns. A computer
model successfully reproduced these findings and implicated I Na
in action potential propagation through the sino-atrial node, from
sino-atrial node to atria, and in modifying heart rate through a
coupling of sino-atrial node and atrial cells. More recently, this
same team has shown that both aging and Scn5a disruption affect
sino-atrial node function through electrical remodeling and TGF-
β1-mediated fibrosis, with the most severe phenotype observed in
old Scn5a± mice (Hao et al., 2011). Interestingly, this in vivo sino-
atrial node dysfunction appears less severe than expected from ex
vivo experiments and computer simulations seems to be due to
an increase in sympathetic regulation of sino-atrial node with age,
partly explained by an over-expression of β1-adrenoceptors (Hao
et al., 2011).
AN OVERLAP SYNDROME MODEL: THE Scn5a1798INSD/+
KNOCK-IN MOUSE
In 1999, a SCN5A mutation (1795insD) associated with an over-
lap syndrome of cardiac Na+ channelopathies was described in
a large Dutch family. The patients’ ECG presented features of
bradycardia, conduction disease, LQT3, and Brugada syndrome
(Bezzina et al., 1999). The analysis of the 1795insD mutation
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biophysical properties led to contrasting results depending on
the heterologous expression system used. In Xenopus oocytes, the
mutation reduced the Na+ current through a negative shift in
voltage-dependence of steady-state inactivation but did not pro-
duce the persistent current commonly observed in LQT3 (Bezzina
et al., 1999). In contrast, in HEK293 cells, 1795insD mutation
disrupted fast inactivation leading to sustained inward Na+ cur-
rent that could prolong repolarization at slow heart rates and,
at the same time, increased slow inactivation, delaying recovery
of Na+ channel availability between stimuli and reducing the
Na+ current under conditions mimicking fast heart rates (Veld-
kamp et al., 2000). Computer modeling showed that this dual
mechanism could indeed explain the overlap syndrome, depend-
ing on the heart rate (Clancy and Rudy, 2002). Because of these
discrepancies and because the co-inheritance of other genetic
variants besides the 1795insD mutation as a cause of the phe-
notype complexity in the family could not be ruled out, Remme
et al. (2006) generated a knock-in mouse carrying the mouse
equivalent (1798insD) of the human SCN5A-1795insD mutation.
Homozygous mice are not viable. Heterozygous Scn5a1798insD/+
mice recapitulate many of the pathological features of the patients
including sinus node dysfunction, conduction slowing, and QT
prolongation at slow rates. Patch-clamp experiments performed
on ventricular Scn5a1798insD/+ cardiomyocytes have shown that
action potential duration was longer than in wild-type cardiomy-
ocytes and that this prolongation was more pronounced at slow
pacing rates. Also, at fast pacing rates, action potential upstroke
velocity, which reflects Na+ channel availability, was reduced
in Scn5a1798insD/+ mice compared to wild-type. However, the
potential biophysical mechanisms thought to explain decreased
availability of Na+ channels in heterologous expression systems
were not confirmed in Scn5a1798insD/+ mice. Indeed, rather than
changes in the voltage-dependence of activation and inactivation
or slow inactivation properties, dysfunctional mutant channels at
the membrane or ineffective trafficking of mutant channels to
the membrane more likely explained the marked decrease of Na+
current in Scn5a1798insD/+ mice. In addition, a small persistent
inward Na+ current was found in Scn5a1798insD/+ cardiomyocytes,
explaining the prolongation of action potential duration and QT
interval. These studies constitute another example of the limita-
tions of heterologous expression systems and illustrate the benefits
of genetically engineered mouse models. In summary, the phe-
notypic characterization of this mouse model has demonstrated
that a single SCN5A mutation is sufficient to cause an overlap
syndrome of cardiac Na+ channel diseases.
This unique model also represented a useful tool to investigate
the impact of genetic and environmental modifiers on cardiac
conduction and repolarization. Indeed, also genetic background
has often been proposed to affect the phenotypic consequences
of ion channel mutations, the identification of genetic modi-
fiers of disease severity in genetically inherited arrhythmias is
rare (Scicluna et al., 2008). In order to identify genetic modi-
fiers of conduction disease, Remme et al. (2009) studied the effect
of the Scn5a-1798insD mutation in mice of two distinct inbred
genetic backgrounds. They showed that the phenotype severity
of mice carrying the Scn5a1798insD/+ mutation varies depend-
ing on the genetic background. This variability is associated with
differential expression of a large number of genes including some
encoding ion channels. In particular, ventricular expression lev-
els of NaV1.5 regulatory β4-subunit (encoded by Scn4b gene)
were markedly reduced in the mouse strain with the most severe
conduction defects, leading to a shift of NaV1.5 channel activa-
tion curve toward more positive voltages and consequently to
a further decrease of I Na. Most recently, these authors went a
step further and applied linkage analysis to a F2 cross resulting
from the two strains carrying the Scn5a-1798insD mutation to
identify quantitative trait loci (QTL) for heart rate, ECG para-
meters, and susceptibility to arrhythmias (Scicluna et al., 2011).
This first genetic mapping analysis for cardiac electrical traits in
mice identified 3 QTL linked with heart rate (chromosome 4),
PR interval (chromosome 3), and QRS interval (chromosome
7) at baseline. Additional significant linkage to chromosome 4
locus was observed for post-flecainide heart rate and ventricular
arrhythmias. Unexpectedly, numerous sex-specific QTLs were also
identified. Finally, QTL for ECG parameters and arrhythmias coin-
cided at five chromosomal locations suggesting pleiotropic effects
at these loci. Interestingly, identified QTLs coincided with chro-
mosomal locations of genes found differentially expressed between
the two parental strains in the prior study (Remme et al., 2009).
This considerably reduces the number of candidate genes respon-
sible for these QTLs. Nevertheless, additional experiments are still
needed to reduce linkage intervals and identify the causal genes.
In spite of their success, genome-wide association studies (GWAS)
performed in large human populations identified only a very small
fraction of heritability of ECG traits and often failed to identify
the causal genes. In this context, QTL analysis studies performed
in mice could provide independent information pointing to the
right genes (Dina, 2011).
AMODEL FOR SCN5A-RELATED DILATED CARDIOMYOPATHY:
THE Scn5a-D1275N MOUSE
The D1275N SCN5A mutation has been related to different car-
diac diseases. It was first reported in a family affected by atrial
standstill, mild conduction disease, and atrial enlargement. How-
ever, all affected members also carried a variant in the connexin
40 promoter (Groenewegen et al., 2003). Subsequently, D1275N
mutation was reported in a family affected by DCM, sinus node
dysfunction, atrial and ventricular tachyarrhythmias and conduc-
tion disorders (McNair et al., 2004; Olson et al., 2005; Ge et al.,
2008). More recently, it was also reported in a family with atrial
tachyarrhythmias, conduction disease, and ventricular enlarge-
ment, but without impaired contractility, as opposed to the previ-
ous family (Laitinen-Forsblom et al., 2006). Finally, this mutation
was also identified in a patient with atrial flutter, atrial standstill,
conduction disease, and sinus node dysfunction (Watanabe et al.,
2011). Despite these phenotypic differences, patch-clamp studies
that have compared wild-type and D1275N channels in heterolo-
gous expression systems have not shown major differences in the
biophysical properties of the mutant channel (Groenewegen et al.,
2003; Gui et al., 2010; Watanabe et al., 2011).
To address this discrepancy, Watanabe et al. (2011) used recom-
binase mediated cassette exchange to engineer a mouse model
expressing the human D1275N mutant channel and compare it
to the mouse model expressing the human wild-type channel
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(Watanabe et al., 2011). The D1275 allele was associated with
slow heart rate and prolonged atrial, atrioventricular and ventric-
ular conduction in a gene-dose-dependent manner, i.e., D1275N
homozygous mice had a more severe phenotype. Interestingly,
conduction disease increased with age. In addition, sinus node
dysfunction, second degree atrioventricular block, atrial tachycar-
dia/fibrillation, and polymorphic ventricular tachycardia occurred
in homozygous D1275N mice. Patch-clamp studies of isolated
cardiomyocytes demonstrated that D1275N mutation causes a
severe decrease in peak I Na by 54% in heterozygous mice and
78% in homozygous mice in relation to a decreased sarcolem-
mal expression of NaV1.5. Moreover, homozygous D1275N mice
exhibited an increased late Na+ current, leading to prolonged
action potential duration. Finally, the mutant was also associated
with a gene-dose-dependent reduction of contractile function and
DCM. These results are in line with the clinical findings described
in the mutation carriers.
Scn1b KNOCKOUT MOUSE
The cardiac Na+ channel is a heterotrimer composed of Nav1.5,
the pore-forming α-subunit, and two auxiliary β-subunits (Mead-
ows and Isom, 2005): a non-covalently linked β1-subunit (NaVβ1
or β3) and a disulfide-linked subunit (NaVβ2 or β4). In a genetic
screening of 282 probands with Brugada syndrome and 44 with
conduction disease, none of whom had mutations in SCN5A gene,
three mutations in the gene encoding NaVβ1 (SCN1B) were iden-
tified in three kindred (Watanabe et al., 2008). Two mutations
were located in a newly described alternately spliced transcript,
NaVβ1B (Qin et al., 2003). Both transcripts are expressed in human
heart and to a greater extent in Purkinje fibers than in ventric-
ular myocardium (Watanabe et al., 2008). The E87Q mutation,
located in the extracellular immunoglobulin loop of both β1- and
β1B-subunits, was identified in a family affected by conduction
disease. The two other mutations, which resulted in a β1B-subunit
truncated after the amino-acid tryptophan-179, were identified
in a family affected with both Brugada syndrome and conduction
disease and in a kindred affected with conduction disease. Electro-
physiological studies showed that peak I Na amplitude was lower
when Nav1.5 was co-expressed with mutant NaVβ1- and NaVβ1B-
subunits versus wild-type subunits. This result was consistent with
the patients’ phenotypes.
The cardiac electrophysiological phenotype of a mouse model
invalidated for Scn1b markedly differed from the phenotype of
the patients presented above (Lopez-Santiago et al., 2007). Com-
pared to wild-type mice, Scn1b knockout mice exhibited lower
heart rates and prolonged QT intervals, without any signs of con-
duction disease. Surprisingly, loss of NaVβ1 expression resulted
in an increase in both peak and persistent Na+ current while
channel gating and kinetics were unaffected. This increase in cur-
rent was most likely due to the increased expression of Nav1.5
observed in these mice. Immunostaining studies revealed no alter-
ations in the localization of Na+ channel α- or β-subunits. Action
potentials were prolonged, supporting the increased QT interval.
These results are consistent with the observation that the D1790G
mutation of SCN5A, which affects the interaction of NaV1.5 with
NaVβ1, also leads to a long QT phenotype (Benhorin et al., 1998;
An et al., 1998). Once again, studies performed in heterologous
expression systems led to contrasting results. Indeed, the D1790G
mutation was first found to shift negatively steady-state inacti-
vation of the Na+ current without increasing its late component
(An et al., 1998). The action potential prolongation was attributed
to alterations of calcium-sensitive exchange and ion channel cur-
rents (Wehrens et al., 2000). By contrast, a second study showed
that the mutation-induced a marked prolongation of the late
Na+ current, a result more consistent with the long QT pheno-
type (Baroudi and Chahine, 2000). Interestingly, the phenotype of
Scn1b knockout mice resembles that found in a family of patients
carrying a mutation on SCN4B, the gene encoding the β4-subunit.
These patients exhibit a markedly prolonged QT interval (LQT10;
Medeiros-Domingo et al., 2007) due to a large increase of the late
Na+ current amplitude, as in LQT3 patients.
Scn3b KNOCKOUT MOUSE
In order to understand better the role of NaVβ3 subunit on NaV1.5
function, Hakim and co-workers generated a mouse model lack-
ing the Scn3b gene (Scn3b−/− mouse; Hakim et al., 2008). They
showed that the lack of NaVβ3 induced a≈30% decrease in cardiac
Na+ peak current amplitude associated with a shift of the steady-
state inactivation curve toward negative potentials while other I Na
biophysical parameters were not altered, thus confirming previous
studies in mammalian heterologous expression system (Ko et al.,
2005). As a consequence, Scn3b] mice exhibited decreased ventric-
ular conduction, shortened ventricular action potential duration,
and refractory period and increased incidence of arrhythmias
under programmed electrical stimulation in ex vivo Langendorff-
perfused hearts (Hakim et al., 2008). Arrhythmogenic incidence
was reduced by flecainide and quinidine (Hakim et al., 2010b), in
contrast to what had been observed previously for flecainide in
Scn5a±mice (Martin et al., 2011c,d). Like Scn5a±mice, Scn3b−/−
mice also exhibited sinus node dysfunction and decreased atrial
and atrioventricular conduction, sometimes leading to atrioven-
tricular block (Hakim et al., 2010a). Finally, Scn3b−/− mice were
more prone than wild-type mice to develop atrial tachycardia and
fibrillation upon burst pacing in ex vivo Langendorff-perfused
hearts. Altogether, these studies suggested that Scn3b gene could
also be involved in cardiac channelopathies in human.
This hypothesis has been confirmed. Indeed, SCN3B mutations
have been identified in patients with either Brugada syndrome
(Hu et al., 2009), idiopathic ventricular fibrillation (Valdivia et al.,
2010) or lone atrial fibrillation (Olesen et al., 2011). All the muta-
tions lead to a loss-of-function of NaVβ3 and consequently a
decrease in cardiac Na+ current.
CONCLUSION
Most mouse models of SCN5A-related cardiac channelopathies
recapitulate most of the diverse clinical phenotypes observed in
patients. However mouse models also have their own limitation
as a phenotype observed in mice may not be encountered in
patients. For example, the Scn1b knockout mouse shows pro-
longed ventricular repolarization, a feature that is not seen in
patients with SCN1B loss-of-function mutations. These discrep-
ancies relate to either species differences or differences between a
heterozygous point mutation and complete invalidation of a gene
on one allele.
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Mouse models also turned out to be powerful tools to eluci-
date the pathophysiological mechanisms of SCN5A-related dis-
eases. For instance, the Scn5a1798insD/+ mouse clearly demon-
strated that a single SCN5A mutation is sufficient to cause
an overlap syndrome. This mouse also illustrated the limita-
tions of heterologous expression systems in the elucidation of
the biophysical consequences of the mutation on the channel
function.
Finally, mouse models of NaV1.5 (or NaV1.5-associated pro-
teins) dysfunction offer the unique opportunity to investigate the
secondary cellular consequences of SCN5A mutations such as the
expression remodeling of other genes, which is hardly accessi-
ble in the hearts of patients, but that might participate to the
overall phenotype and explain some of the differences among
patients. The most exiting benefit of mouse models is that they
raise new working hypotheses such as the putative link between
NaV1.5 loss-of-function and occurrence of fibrosis in the context
of PCCD, thereby providing new potential therapeutic approaches.
One limitation, though, is that remodeling might be partly species
dependent. They also constitute useful tools for future stud-
ies addressing as yet unanswered questions, such as the role of
genetic and environmental modifiers on cardiac conduction and
repolarization.
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